Ropes & Gray advised Carbylan Therapeutics, Inc. in its underwritten initial public offering of 14,950,000 shares of common stock at $5 per share, which includes the exercise by the underwriters of their option to purchase up to 1,950,000 additional shares. The shares began trading on Nasdaq on April 9 under the symbol “CBYL,” and the offering closed on April 14. Carbylan estimates net proceeds from the offering to be approximately $66.1 million, after deducting underwriting discounts and commissions and estimated offering expenses. Palo Alto, Calif.-based Carbylan is a clinical-stage specialty pharmaceutical company, which is currently developing an injectable treatment for osteoarthritis pain in the knee.
The Ropes & Gray team included benefits associates Jennifer Rikoski (Boston) and Danna Kivell (New York).
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.